A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
Neurology 2017 Jan 2;88(2):152-159. Epub 2016 Dec 2.
From Cooper University Healthcare at Rowan University (A.M.), Camden, NJ; University of Rochester (M.M., K.K., E.A.d.B., K.B., P.C.); Weill Cornell Medical Center (F.B.); Columbia Presbyterian Medical Center (K.M.), New York, NY; Johns Hopkins Medical Center (C.R.), Baltimore, MD; Georgetown University (I.S.), Washington, DC; NINDS (P.G.), Bethesda, MD; Hereditary Neurological Disease Center (W.M.M.), Wichita, KS; The Centre for Movement Disorders (M.G.), Toronto, Canada; Indiana University School of Medicine (J.W.), Indianapolis; Colorado Neurological Institute (R.K.), Englewood; University of Tennessee Health Science Center (M.S.L.), Memphis; London Health Sciences Centre (M.J.), Canada; Massachusetts General Hospital (H.D.R.), Boston; Struthers Parkinson's Center (M.N.), Minneapolis, MN; University of Kansas Medical Center (R.M.D.), Kansas City; Rush University Medical Center (K.M.S.), Chicago, IL; University of Texas Southwestern Medical Center (P.O.), Dallas; University of Michigan (K.C.), Ann Arbor; Wake Forest University (F.W.), Winston-Salem, NC; University of Alberta (W.M.), Edmonton, Canada; University of California Davis (V.L.W.), Sacramento; Westmead Hospital (E. McCusker), Westmead, Australia; Baylor College of Medicine (J.J.), Houston, TX; University of Miami Miller School of Medicine (C.S.), FL; University of South Florida (J.S.-R.), Tampa; Duke University (B.S.), Durham, NC; University of Calgary (O.S.), Canada; Emory University School of Medicine (S.A.F.), Atlanta, GA; Albany Medical College (D.S.H., Eric Molho), NY; University of Cincinnati (F.R.), OH; Mayo Clinic Arizona (J.N.C.), Scottsdale; Butler Hospital (J.H.F.), Providence, RI; Washington University (J.S.P.), St. Louis, MO; Feinstein Institute for Medical Research (A.F.), Manhasset, NY; Georgetown University (K.A.), Washington, DC; University of Florida (R.R., N.R.M.), Gainesville; Johns Hopkins University (R.L.M.), Baltimore, MD; University of Nevada School of Medicine (E.S.F.), Reno; University of British Columbia (L.A.R.), Vancouver, Canada; University of Pittsburgh (V.S.), PA; Ohio State University (S.K.), Columbus; The Cooper University Health System (A.C.), Camden, NJ; Idaho Elks Rehabilitation Hospital (L.S.), Boise, ID; University of Iowa (E.E.), Iowa City; North York General Hospital 1 (S.E.), Toronto, Canada; St. Luke's Hospital (N.D.), Allentown, PA; North York General Hospital 2 (W.L.A.F.), University of Toronto, Canada; Washington Regional Medical Center (A.D.), Fayetteville, AR; Beth-Israel Deaconess Medical Center (S.F.), Boston, MA; NJ Neuroscience Institute (P.H.), Edison; University of California Irvine (N.H.); The University of Alabama at Birmingham (L.S.D.); and Massachusetts General Hospital (M.C.), Harvard Medical School, Boston.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
JAMA Neurol 2016 Jan;73(1):102-10
Department of Neuroscience, University of California, San Diego, La Jolla.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.
Brain 2015 Sep 28;138(Pt 9):2659-71. Epub 2015 Jul 28.
1 Neurogenomics Lab and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Cambridge, MA 02139, USA 2 Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA 4 Ann Romney Centre for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA 5 Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA 02115, USA 7 Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA

Mendelian randomization of serum urate and parkinson disease progression.
Ann Neurol 2014 Dec 3;76(6):862-8. Epub 2014 Oct 3.
Department of Nutrition, Harvard School of Public Health, Boston, MA; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.
Mov Disord 2014 May 11;29(6):743-9. Epub 2014 Feb 11.
Clinical Research, The Parkinson's Institute, Sunnyvale, California, USA; Department of Health Research and Policy, Stanford University, Palo Alto, California, USA.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
JAMA Neurol 2014 May;71(5):543-52
Department of Neurology, Beth Israel Medical Center, New York, New York.

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Neurology 2014 May 23;82(20):1791-7. Epub 2014 Apr 23.
From the Institute for Neurodegenerative Disorders (K.M., J.S., D.J.), University of Rochester (S.E., D.O.), Rochester, NY; Georgetown University (I.S.), Washington, DC; University of Toronto (A.E.L.); and Western University (C.H.), London, Ontario, Canada.

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Pharmacogenet Genomics 2014 Feb;24(2):81-93
aInnovation Center for Biomedical Informatics bLombardi Comprehensive Cancer Center, Developmental Therapeutics Program cDepartment of Neurology, Georgetown University Medical Center dDepartment of Mathematics and Statistics, Georgetown University, Washington, District of Columbia eESAC Inc., Rockville fUS Food and Drug Administration, Silver Spring, Maryland, USA.

Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
Mov Disord 2013 Dec 9;28(14):1980-6. Epub 2013 Oct 9.
Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.
Neurology 2013 Sep 21;81(13):1134-40. Epub 2013 Aug 21.
From the Massachusetts General Hospital (M.M.-L., R.E.G., J.J.R., H.D.R., S.M., A.B.Y., S.M.H.), MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Charlestown, MA; University of Rochester Medical Center (S.E., D.O.), Department of Biostatistics and Computational Biology, Rochester, NY; Veterans Administration Hospital (W.M.), Bedford, MA; and Program for Regulatory Science & Medicine (I.S.), Georgetown University, Washington, DC.

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study.
PLoS Curr 2011 Nov 13;3:RRN1283. Epub 2011 Nov 13.
Neurologist, Johns Hopkins University; Department of Neurology, University of Rochester, Rochester, NY, USA; University of Rochester Medical Center, Rochester NY; Movement Disorders Fellow, Johns Hopkins University; Partner, KM Pharmaceutical Consulting; Associate Professor of Neurology, University of Rochester School of Medicine and Dentistry; Professor of Neurology, Pharmacology & Human Science. Director, Program for Regulatory Science & Medicine (PRSM) and Doctor.

Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study.
Am J Med Genet B Neuropsychiatr Genet 2010 Jul;153B(5):1081-93
Department of Family Medicine, John P. McGovern Center for Health, Humanities and the Human Spirit, University of Texas Medical School at Houston, Houston, Texas, USA.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.
Lancet Neurol 2017 08 16;16(8):620-629. Epub 2017 Jun 16.
Neurogenomics Laboratory and Parkinson Personalized Medicine Program of Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA, USA. Electronic address: